OR WAIT null SECS
December 07, 2016
Previous hesitation by pharma industry to use cocrystals may change with FDA’s new guidance that classifies cocrystals APIs.
December 02, 2016
Non-precious-metal catalysts are increasingly employed for commercial API synthesis.
November 28, 2016
Patheon adds API manufacturing capacity with acquisition of Roche’s Florence, SC facility.
November 02, 2016
New catalysts show promise for pharmaceutical intermediate and API synthesis.
FDA redefines cocrystals as APIs and not drug-product intermediates.
Recipharm is investing more than EUR1.2 million to enhance its small-scale GMP API development and manufacturing capabilities in Paderno Dugnano, Italy.
October 03, 2016
he guidance addresses the good manufacturing practice for managing quality in APIs.
October 02, 2016
Researchers develop catalysts that mediate complex transformations under conditions appropriate for commercial manufacture.
September 20, 2016
The certification follows a successful inspection by the MHRA, with no critical or major observations. The site is now ready to start production.
September 12, 2016
Saneca Pharma is making significant investment in its API capabilities to support client demand for smaller batch sizes and streamlined scale-up.